{ "items": [ "\n\n
\n \n\n \n \n \n \n MOCRU\n \n \n\n \n\n\n
\n \n\n \n17 July 2019
\n \n \n \nMedical Action Myanmar and MOCRU health teams identified a number of children with rickets in remote areas of Myanmar. MOCRU director Frank Smithuis presented the findings of clinical screening to the Minister of Health, alongside treatment results and a plan for a large survey to investigate the prevalence of vitamin D deficiency and its underlying causes.
\n \n\n \n \n\n \n\n \n \n \n \n SMRU\n \n \n\n \n\n\n
\n \n\n \n2 July 2019
\n \n \n \nNew research by Makoto Saito and colleagues at SMRU found that a longer follow-up is required to assess antimalarial drug efficacy in pregnant women. This was found across all drugs assessed in low malaria transmission settings. The report\u2019s authors have called for guidelines specifically for pregnant women and further investigation of optimal follow-up periods in high malaria transmission settings.
\n \n\n \n \n\n \n\n \n \n \n \n MORU Bangkok\n \n \n\n \n\n\n
\n \n\n \n30 April 2019
\n \n \n \nTo mark World Malaria Day on 25 April WWARN\u2019s Dr Makoto Saito and Professor Joel Tarning from the Mahidol Oxford Tropical Medicine Research Unit and Head of WWARN Pharmacometrics presented their work on prevention and treatment of malaria in vulnerable groups at a seminar hosted by the Centre for Tropical Medicine and Global Health
\n \n\n \n \n\n \n\n \n \n \n \n MORU Bangkok\n \n \n\n \n\n\n
\n \n\n \n3 April 2019
\n \n \n \nHow do you go about building all the skills you need at the start of your research career? Cherry Lim from our MORU unit in Bangkok, Thailand, was lucky to find a good mentor who guided her through this journey, but her own ceaseless curiosity and excitement about research were also important.
\n \n\n \n \n\n \n\n \n \n \n \n MORU Bangkok\n \n \n\n \n\n\n
\n \n\n \n26 March 2019
\n \n \n \nRob van der Pluijm presented encouraging findings from TRAC II trial analyses of Triple Artemisinin Combination Therapies to the All-Party Parliamentary Group on Malaria & NTDs on March 19th in Westminster at the Houses of Parliament.
\n \n\n \n \n\n \n\n \n \n \n \n MORU Bangkok\n \n \n\n \n\n\n
\n \n\n \n6 March 2019
\n \n \n \nLorenz Von Seidlein tells SciDev.Net that mass drug administration as \u201cpresumptive treatment\u201d to clear the parasite reservoir was carried out in eight villages spread across Cambodia, Lao PDR, Myanmar and Vietnam. By the third month, the prevalence of P. falciparum had decreased by 92 % in those villages. Over the subsequent nine months, P. falciparum infections returned but stayed well below baseline levels, showing that MDA can stop transmission of falciparum malaria and reduce its prevalence in SE Asia, where resistance to artemisinin has hampered elimination efforts.
\n \n\n \n \n\n \n\n \n \n \n \n KIMORU\n \n \n\n \n\n\n
\n \n\n \n1 March 2019
\n \n \n \nWorking closely with the University of British Columbia (UBC)'s Support Program to Advance Research Capacity (SPARC), MORU Malaria Researcher Dr Katherine Plewes was recently awarded a 3-year, C$971,551 grant for her study on Evaluating the renoprotective effect of acetaminophen in pediatric severe falciparum malaria: A randomized controlled trial.
\n \n\n \n \n\n \n\n \n \n \n \n MORU Bangkok\n \n \n\n \n\n\n
\n \n\n \n12 February 2019
\n \n \n \nOn 24-25 Jan 2019, investigators met in Bangkok to launch the Developing Triple Artemisinin-based Combination Therapies (DeTACT) Project. Led by MORU and funded by UKaid and the UK Department for International Development (DfID), DeTACT is a large, 14 site trial in 8 African and 5 Asian countries that will study the efficacy, safety and tolerability of two Triple Artemisinin Combination Therapy (TACT) combinations, using combinations of existing antimalarial drugs.
\n \n\n \n \n\n \n\n \n \n \n \n MORU Bangkok\n \n \n\n \n\n\n
\n \n\n \n18 January 2019
\n \n \n \nA recent WWARN individual patient meta-analysis has gathered 18 published and unpublished studies from Africa and Asia to explore the relationships between identified Kelch 13 mutant alleles and delayed parasite clearance. The study results show one P. falciparum specific mutant and 20 pfk13 propeller region mutant alleles are strongly associated with the slow clearance phenotype, including 15 mutations that have not been confirmed before. It was reassuring that no pfk13 alleles associated with slow parasite clearance were observed in the parasites from African studies gathered between 2000-2017.
\n \n\n \n \n\n \n\n \n \n \n \n COMRU\n \n \n \n \n General\n \n \n\n \n\n\n
\n \n\n \n16 January 2019
\n \n \n \nMalaria causes nearly half a million deaths worldwide every year. Ninety percent of them are in sub-Saharan Africa, where poor infrastructure limits delivery of drugs. But now there is worry that those drugs are losing effectiveness as disease strains become resistant. PBS News Hour special correspondent Fred de Sam Lazaro reports from Cambodia, where scientists are researching and tracking new outbreaks.
\n \n\n \n \n\n \n\n \n \n \n \n MORU Bangkok\n \n \n\n \n\n\n
\n \n\n \n16 January 2019
\n \n \n \nDoctors in Northern Cambodia are trialling a new drug combination therapy in a bid to stop the spread of drug resistant strains of malaria.
\n \n\n \n \n\n \n\n \n \n \n \n MORU Bangkok\n \n \n\n \n\n\n
\n \n\n \n18 December 2018
\n \n \n \nA new Piperaquine Pharmacokinetics in Pregnancy Study Group is now open for participation at WWARN. The analysis hopes to determine the effect of pregnancy on the pharmacokinetic (PK) properties of piperaquine and contribute evidence to inform decisions on the use and optimal dosing of piperaquine in pregnant women.
\n \n\n \n \n\n \n\n \n \n \n \n MORU Bangkok\n \n \n\n \n\n\n
\n \n\n \n20 November 2018
\n \n \n \nProgress against malaria has stalled, and the disease remains a significant threat to billions of people despite the expensive, decades-long efforts to contain it. In an encouraging development, MORU reported complete success in curing hundreds of patients in Southeast Asia with new three-drug combinations mixing fast-acting artemisinin with two longer-lasting drugs. It it hoped that triple therapy should become the standard for malaria treatment.
\n \n\n \n \n\n \n\n \n \n \n \n MORU Bangkok\n \n \n\n \n\n\n
\n \n\n \n9 November 2018
\n \n \n \nA systematic review analyses the results of 177 trials conducted between 1982 and 2016, including 18,436 patients who underwent electrocardiographic evaluation during malaria clinical trials. Nick White and colleagues found that serious cardiovascular side effects, which include sudden cardiac death, are very rare in the treatment of malaria with quinoline antimalarials. The work emphasises the importance of continued pharmacovigilance with the increasing use of quinoline antimalarials in mass treatment strategies such as intermittent preventative treatment and mass drug administration.
\n \n\n \n \n\n \n\n \n \n \n \n MOCRU\n \n \n\n \n\n\n
\n \n\n \n7 November 2018
\n \n \n \nThe incidence of malaria has continued to drop dramatically in remote rural villages in Myanmar after community workers trained only to detect and treat malaria began providing basic health care as well as malaria services, researchers affiliated with MOCRU, our Myanmar-Oxford Clinical Research Unit, have said.
\n \n\n \n \n\n \n\n \n \n \n \n MOCRU\n \n \n\n \n\n\n
\n \n\n \n24 October 2018
\n \n \n \nThe incidence of malaria cases continued to drop dramatically in rural and remote Myanmar villages after community workers trained only to detect and treat malaria began providing basic health care as well as malaria services. Adding the health services to malaria control benefitted the villagers access to health and improved malaria services \u2013 paving the way for malaria elimination.
\n \n\n \n \n\n \n\n \n \n \n \n MORU Bangkok\n \n \n\n \n\n\n
\n \n\n \n28 September 2018
\n \n \n \nIn this Science blog, field researchers, Dr Giacomo Zanello, Dr Marco Haenssgen, Ms Nutcha Charoenboon and Mr Jeffrey Lienert explain the importance of continuing to improve survey research techniques when working in rural areas of developing countries.
\n \n\n \n \n\n \n\n \n \n \n \n MORU Bangkok\n \n \n\n \n\n\n
\n \n\n \n12 September 2018
\n \n \n \nMORU is participating in a project to reduce antibiotic resistance on farms in Asia by educating farmers. In his first 12 years working as a vet in Bangladesh, Bikash Chandra Saha routinely prescribed antibiotics. Then he learned of the devastating impact of antimicrobial resistance on human health - and it revolutionized his treatment choices.
\n \n\n \n \n\n \n\n \n \n \n \n MOCRU\n \n \n\n \n\n\n
\n \n\n \n12 September 2018
\n \n \n \nDr Myo Maung Maung Swe and Htet Htet Aung from our MOCRU unit in Myanmar were awarded grants by the International Society for Infectious Diseases and Wellcome. Myo Maung will study antibiotics use and antimicrobial resistance public awareness in Myanmar; Htet Htet will conduct a study on Ethical challenges when offering pregnant women with Hepatitis B short course treatment to prevent transmission.
\n \n\n \n \n\n \n\n \n \n \n \n MORU Bangkok\n \n \n\n \n\n\n
\n \n\n \n4 September 2018
\n \n \n \nA team of researchers led by Yoel Lubell at MORU and IDDO used data from the USA and Thailand to link the consumption of antibiotics with the direct and indirect costs of treating patients for five drug-resistant bacterial infections.
\n \n\n \n \n